CSI Laboratories Advances Precision in Cancer Diagnostics by Partnering with Dr. Maher Albitar of Genomics Testing Cooperative (GTC)

The partnership’s focus on quality and technology has already made CSI Laboratories the first in the market to offer 177 gene panel liquid biopsy for hematology – accelerating cancer diagnostic speed and accuracy. The combined menu of CSI Laboratories and GTC tests represents the most comprehensive and innovative offering in cancer patient profiling on the market.

“CSI Laboratories is continuously leveraging state-of-the-art technology and medical experience to give pathologists and oncologists the information they need to provide the best patient care,” said Ron Ghafary, President and Founder of CSI Laboratories. “We are excited about a partnership that innovates for our clients as well as the marketplace,” he added.

Dr. Maher Albitar, founder of GTC and former Senior Vice President, Chief Medical Officer, and Director of R & D at NeoGenomics Laboratories, will be hosting a webinar alongside CSI Laboratories’ esteemed Medical Director, Dr. Lawrence Hertzberg, M.D., to discuss the partnership’s goals and forthcoming capabilities regarding cancer diagnostics.

MOLECULAR PATHOLOGY WEBINAR
Next Generation Sequencing in the practice of Precision Medicine
January 10, 2019
2pm EST
RSVP: https://bit.ly/2Qtj9N9

“I am very pleased to be working with the team at CSI Laboratories and we are excited about enabling them to offer the most innovative and comprehensive molecular profiling for hematologic and solid tumors,” said Dr. Albitar. “When combined with the innovative, comprehensive and affordable molecular profiling of GTC, the patient-centered personalized pathology services offered at CSI will enable physicians to make the right decision for their patients with more accuracy than ever before,” he added.

CSI Laboratories’ clients benefit from having access to an experienced medical team, highly trained technologists and expert scientific advisors dedicated to ensuring the details of every test result are understood in order to personalize patient treatment plans.

According to Dr. Hertzberg, “CSI is very excited about offering next generation sequencing (NGS) services to all of our clients at a reasonable price by partnering with GTC. We anticipate enhanced diagnostic capability - including possible referral of patients to clinical trials based upon NGS results. “

To learn more about the partnership between CSI Laboratories and Genomic Testing Cooperative (GTC), please contact info@csilaboratories.com. To register for the upcoming webinar, please visit https://bit.ly/2Qtj9N9.

ABOUT CSI LABORATORIES

CSI Laboratories is a specialized cancer diagnostics laboratory focused specifically on meeting the unique needs and challenges of pathologists and community hospitals. CSI Laboratories offers flow cytometry, cytogenetic analysis, fluorescence in-situ hybridization (FISH), immunohistochemistry, molecular genetics, and consultations in the areas of hematopathology and surgical pathology. CSI Laboratories is a CLIA-certified and CAP-accredited laboratory located in Alpharetta, GA. CSI Laboratories is independently owned and operated by medical professionals and has provided expert diagnostic testing to pathologists across the United States since 1997. For more information, please visit www.csilaboratories.com.

ABOUT GENOMIC TESTING COOPERATIVE

Genomic Testing Cooperative (GTC) is a privately-owned molecular testing company located in Irvine, CA. The company offers its patron members a full suite of comprehensive genomic profiling based mainly on next generation sequencing. Molecular alterations are identified based on rigorous testing with the aid of specially developed algorithms to increase accuracy and efficiency. The co-op model allows GTC to make the testing and information platform available to members at a lower cost because of a lower overhead. For more information, please visit https://genomictestingcooperative.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181205005474/en/